Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 3Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Dermatologic 2Breast 2Other solid neoplasm 1Lymphoid 1

Conditions

Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Melanoma 5Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Lymphoma 2Endometrial Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Mesothelioma 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 19Paclitaxel 6Trastuzumab 5Nivolumab 5palbociclib 4Carboplatin 4Biopsy 4lenvatinib 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunoglobulin G 3Fulvestrant 3Cyclophosphamide 3Cetuximab 3trastuzumab deruxtecan 2tisotumab vedotin 2spartalizumab 2sargramostim 2gedatolisib 2fludarabine 2epacadostat 2capivasertib 2X-Rays 2Sunitinib 2Docetaxel 2Disulfides 2Cisplatin 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Endometrial Neoplasms × epacadostat × Head & Neck × Clear all
NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT03277352 2021-07-22

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Terminated
10 enrolled 14 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡